Last deal

$20M

Amount

Series C

Stage

25.06.2024

Date

3

all rounds

$344M

Total amount

date founded

Financing round

General

About Company
Frontier Medicines is a precision medicine company that develops a chemoproteomics platform to accelerate drug discovery.

Industry

Sector :

Subsector :

Keywords :

founded date

01.01.2018

founders

Number of employees

Company Type

For Profit

Last funding type

Series C

IPO status

Private

Description

By integrating advanced computational approaches and machine learning, the platform discovers and targets new binding pockets on proteins, making them accessible to small-molecule drug discovery and development. This enables healthcare professionals to provide breakthrough medicines for debilitating diseases. Located in South San Francisco, CA and Boston, MA, Frontier Medicines is pioneering a powerful discovery and development platform to generate medicines against disease-causing proteins previously considered undruggable. Their lead program targets KRAS G12C, a validated driver in several cancers that was previously undruggable.
Contacts
Legal Names

Legal name

Frontier Medicines Corporation
Similar Companies
1000
FogPharma

FogPharma

FogPharma develops cell-penetrating mini proteins to treat cancer.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Pharmaceuticals, Health Care

Location

Cambridge, MA, USA

total rounds

6

total raised

$530.27M
Arrakis Therapeutics

Arrakis Therapeutics

Arrakis Therapeutics develops drugs to treat neurological disorders and other diseases using a drug discovery platform that targets RNA.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Health Care, Pharmaceuticals

Location

Waltham, MA, USA

total rounds

2

total raised

$113M
Triana Biomedicines

Triana Biomedicines

Triana Biomedicines develops a molecular glue discovery platform to regulate disease.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

Waltham, MA, USA

total rounds

4

total raised

$160.8M
Mersana Therapeutics

Mersana Therapeutics

Mersana Therapeutics develops a biodegradable polymer platform to create new and better medicines.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Health Care, Pharmaceuticals

Location

Cambridge, MA, USA

total rounds

12

total raised

$580.61M

Financials

Funding Rounds
5
3

Number of Funding Rounds

$344M

Money Raised

Their latest funding was raised on 25.06.2024. Their latest investor ArrowMark Partners. Their latest round Series C

Date 
Funding Round 
Investors 
Money Raised 
Lead 
25.06.2024
2
$20M
19.07.2021
10
$88.5M
Droia Ventures

Droia Ventures

Droia is a biotech investor that invests exclusively in oncology and genetic disease therapies.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

Luxembourg District, Luxembourg

count Of Investments

27
Deerfield Management

Deerfield Management

Deerfield Management is a healthcare company that focuses on advancing healthcare through investment, information, and philanthropy.

Sector

Health Care Providers

Subsector

Health Care Management Services

Keywords

Health Care

count Of Investments

19
Woodline Partners

Woodline Partners

Woodline Partners is a San Francisco-based investment firm specializing in healthcare and technology sectors.

Sector

Investment Banking and Brokerage Services

Subsector

Asset Managers and Custodians

Location

San Francisco, CA, USA

count Of Investments

47

count Of Exists

3
Co-Investors
Investors
12
4

Number of lead investors

12

Number of investors

Investor 
Lead 
Round 
Partners 
No
Series B, Series C
No
Series B, Series C
No
Series B, Series C
ArrowMark Partners

ArrowMark Partners

ArrowMark Partners is an employee-owned asset management firm founded in 2007.

Sector

Investment Banking and Brokerage Services

Subsector

Asset Managers and Custodians

Keywords

Financial Services, Internet, Asset Management

Location

Denver, CO, USA

count Of Investments

61

count Of Exists

5
Deep Track Capital

Deep Track Capital

Deep Track Capital is a Greenwich-based investment firm focused on life sciences.

Sector

Investment Banking and Brokerage Services

Subsector

Asset Managers and Custodians

Location

Greenwich, CT, USA

count Of Investments

60

count Of Exists

1
DCVC Bio

DCVC Bio

DCVC Bio is a venture capital fund that invests in early-stage life science companies driven by deep-tech approaches.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Financial Services, Venture Capital

Location

San Francisco, CA, USA

count Of Investments

45

count Of Exists

1

People

Founders
1
Chris Varma
Chris Varma

Chris Varma

Chris joined Flagship in 2007 as Partner and focuses primarily on Life Science investments. He came to Flagship with significant management experience in clinical development, regulatory strategy, business development, sales, and marketing in the pharmaceutical industry. Prior to Flagship, Chris was with Novartis Pharmaceuticals since 2004 where he served most recently as Director of the Tekturna (aliskiren) marketing team responsible for all Medical Marketing, Medical Strategy, and Professional Promotions activities in the U.S. Chris also oversaw Tekturna�s extensive clinical development programs, and played a key role in the FDA approval, CMS reimbursement coverage approval, and successful commercial launch of Tekturna in early 2007. Previously at Novartis, Chris was Director of Business Development & Licensing where he identified several in-licensing opportunities and drove key transactions. Prior to that, Chris focused on corporate strategy working directly with the Novartis Pharma CEO in Basel, Switzerland. Before Novartis, Chris was a consultant for Millennium Pharmaceuticals working on special projects in the Personalized Medicine Group. Before Millennium, Chris worked for the US Food and Drug Administration (FDA) in the Office of Combination Products coordinating and managing reviews across the major Centers. Early in his career he co-founded Epitrope Corporation, a company that developed server-side solutions for wireless telecom carriers.

current job

Frontier Medicines
Frontier Medicines

Chris Varma

Employee Profiles
5
Marguerite Hutchinson

Marguerite Hutchinson

Chief Business Officer

Daniel Erlanson

Vice president of chemistry

Daniel A. Erlanson

VP of Chemistry

Chris Varma

Chris Varma

Founder, President & CEO

Tina Gullotta

Tina Gullotta

Vice President Finance

Activity

Recent News
1